Suppr超能文献

下一代预防性人乳头瘤病毒疫苗。

Next generation prophylactic human papillomavirus vaccines.

机构信息

National Cancer Institute National Institute of Health, Bethesda, MD, USA.

Deutsches Krebsforschungzentrum, Heidelberg, Germany.

出版信息

Lancet Oncol. 2015 May;16(5):e217-25. doi: 10.1016/S1470-2045(14)71179-9.

Abstract

The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe, effective, and well established prophylactic vaccines. However, they have some inherent limitations, including a fairly high production and delivery cost, virus-type restricted protection, and no reported therapeutic activity, which might be addressed with the development of alternative dosing schedules and vaccine products. A change from a three-dose to a two-dose protocol for the licensed HPV vaccines, especially in younger adolescents (aged 9-13 years), is underway in several countries and is likely to become the future norm. Preliminary evidence suggests that recipients of HPV vaccines might derive prophylactic benefits from one dose of the bivalent vaccine. Substantial interest exists in both the academic and industrial sectors in the development of second-generation L1 VLP vaccines in terms of cost reduction-eg, by production in Escherichia coli or alternative types of yeast. However, Merck's nonavalent vaccine, produced via the Saccharomyces cerevisiae production system that is also used for their quadrivalent vaccine, is the first second-generation HPV VLP vaccine to be available on the market. By contrast, other pharmaceutical companies are developing microbial vectors that deliver L1 genes. These two approaches would add an HPV component to existing live attenuated vaccines for measles and typhoid fever. Prophylactic vaccines that are based on induction of broadly cross-neutralising antibodies to L2, the minor HPV capsid protein, are also being developed both as simple monomeric fusion proteins and as virus-like display vaccines. The strong interest in developing the next generation of vaccines, particularly by manufacturers in middle-to-high income countries, increases the likelihood that vaccine production will become decentralised with the hope that effective HPV vaccines will be made increasingly available in low-resource settings where they are most needed.

摘要

两种已许可的二价和四价人乳头瘤病毒(HPV)L1(主要的乳头瘤病毒病毒样颗粒(VLP)衣壳蛋白)疫苗被认为是安全、有效且成熟的预防性疫苗。然而,它们存在一些固有的局限性,包括相当高的生产成本和交付成本、病毒类型限制的保护以及没有报告的治疗活性,这些问题可能通过开发替代剂量方案和疫苗产品来解决。在几个国家,已许可的 HPV 疫苗从三剂方案改为两剂方案,特别是在较年轻的青少年(9-13 岁)中,正在进行中,这可能成为未来的规范。初步证据表明,HPV 疫苗的接种者可能从一剂二价疫苗中获得预防性益处。学术界和工业界都对第二代 L1 VLP 疫苗的开发产生了浓厚的兴趣,以降低成本,例如在大肠杆菌中生产或使用其他类型的酵母。然而,默克公司的九价疫苗是第一种可在市场上获得的第二代 HPV VLP 疫苗,该疫苗通过酿酒酵母生产系统生产,也用于他们的四价疫苗。相比之下,其他制药公司正在开发可传递 L1 基因的微生物载体。这两种方法将在现有的麻疹和伤寒减毒活疫苗中添加 HPV 成分。基于诱导对 HPV 次要衣壳蛋白 L2 的广泛交叉中和抗体的预防性疫苗也在开发中,包括作为简单的单体融合蛋白和病毒样展示疫苗。开发下一代疫苗的强烈兴趣,特别是中高收入国家的制造商,增加了疫苗生产分散化的可能性,希望在最需要的资源有限的环境中,更有效地提供 HPV 疫苗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验